CIK: 0000872589 · Show all filings
Period: Q4 2025 (← Previous)
Filing Date: Feb 6, 2026
Total Value ($000): $33,799 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 1,392,303 | $634,890 | 1878.4% | $262.99 | +68.3% | — | 02043Q107 |
| — | Adverum Biotechnologies, Inc. | 180,909 | $820 | 2.4% | $4.67 | — | — | 00773U207 |
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Adicet Bio, Inc. | 60,511 (-93.8%) | $510 (-35.0%) | 1.5% | $0.96 | — | Common Stock | 007002108 |
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | 3,702,995 | $33,290 | 98.5% | $15.61 | -11.8% | Common Stock | 45826J105 |